Anti-inflammatory activity

Key anti-inflammatory herbal compounds—curcumin, curcumin analogues, resveratrol, boswellic acids derived from Boswellia serrata, and Tripterygium wilfordii extracts—are reviewed in this study, together with mechanistic in vitro data and translational implications, for the management of rheumatoid arthritis (RA). This research provides a summary of their molecular processes, which include cytokine suppression, NF-κB inhibition, antioxidant action, and immunological modulation, based solely on recent systematic reviews, meta-analyses, preclinical evaluations, and randomized trials. Emerging clinical translation in autoimmune illnesses and osteoarthritis is supported by good molecular evidence for these herbs, especially curcumin, resveratrol, and boswellic acids. Bioavailability, consistent dosage, and long-term safety are still areas where research is lacking in RA. Optimized formulations, high-quality RA-specific clinical studies, and mechanistic validation through in vitro disease models should be the priorities of future research.

The application of herbal drugs has become an extensive part of the human history because the drug has been in use since centuries and all over the continents of Ayurveda in India, Traditional Chinese Medicine (TCM), to the traditional African and Native American medicine systems because the drug has been the major provider of health care before the emergence of synthetic drugs. However, the systematic adoption into health care systems has not been expeditious, consistent and consistent enough so as to be able to hold an adjuvative or substitute position, but not necessarily fit in the mainstream clinical practice. It is a literature review of the evolving role of herbal medicine in contemporary healthcare based on critical analysis of existing literature on its effectiveness, safety, pharmacological and regulatory acceptability in other locations. Such points are historical concepts, treatment role in the management of the chronic and lifestyle-based condition, advances in the clinical research, the persisting issues of standardization and quality control, and the potential of the national and international regulatory body to ensure authenticity and safety.